PMN ProMIS Neurosciences Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1374339 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-32.5%
TTM EPS YoY62.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-152.3%
ROA-113.1%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets11.4%
Debt / equity0.00x
Current ratio8.83x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.07x
Accruals ratio7.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | — | — |
| R&D expense | $33.38M | $10.64M |
| SG&A expense | $6.79M | $6.19M |
| Operating income | -$40.17M | -$16.83M |
| Income tax | — | $0 |
| Net income | -$39.72M | $2.78M |
| EPS (basic) | -22.61 | 2.68 |
| EPS (diluted) | -22.61 | 2.63 |
| Weighted avg. shares (diluted) | 1.76M | 1.06M |
| Balance sheet | ||
| Cash & equivalents | $6.12M | $13.29M |
| Short-term investments | $33,753 | $33,051 |
| Current assets | $9.18M | $18.91M |
| Total assets | $9.18M | $18.91M |
| Current liabilities | $10.41M | $2.22M |
| Total liabilities | $10.44M | $2.42M |
| Shareholders' equity | -$1.26M | $16.49M |
| Shares outstanding | 2.15M | 1.31M |
| Cash flow statement | ||
| Operating cash flow | -$28.12M | -$27.18M |
| Investing cash flow | -$702 | -$693 |
| Financing cash flow | $20.94M | $27.88M |
| Stock-based compensation | $857,628 | $825,808 |
Free plan shows the latest 2 periods; Pro shows all 5 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.